CL2019001226A1 - Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) activables y sus usos. - Google Patents
Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) activables y sus usos.Info
- Publication number
- CL2019001226A1 CL2019001226A1 CL2019001226A CL2019001226A CL2019001226A1 CL 2019001226 A1 CL2019001226 A1 CL 2019001226A1 CL 2019001226 A CL2019001226 A CL 2019001226A CL 2019001226 A CL2019001226 A CL 2019001226A CL 2019001226 A1 CL2019001226 A1 CL 2019001226A1
- Authority
- CL
- Chile
- Prior art keywords
- ctla
- tumor
- antibodies
- rest
- activable
- Prior art date
Links
- 102000008203 CTLA-4 Antigen Human genes 0.000 title abstract 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 title abstract 2
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 2
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 230000000873 masking effect Effects 0.000 abstract 1
- 230000002797 proteolythic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662417212P | 2016-11-03 | 2016-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001226A1 true CL2019001226A1 (es) | 2019-09-13 |
Family
ID=61132883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001226A CL2019001226A1 (es) | 2016-11-03 | 2019-05-03 | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) activables y sus usos. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11117968B2 (enExample) |
| EP (1) | EP3535300B1 (enExample) |
| JP (2) | JP7039582B2 (enExample) |
| KR (2) | KR102584340B1 (enExample) |
| CN (1) | CN110072890B (enExample) |
| AR (1) | AR110678A1 (enExample) |
| AU (1) | AU2017355446A1 (enExample) |
| BR (1) | BR112019008223A2 (enExample) |
| CA (1) | CA3042679A1 (enExample) |
| CL (1) | CL2019001226A1 (enExample) |
| CO (1) | CO2019004469A2 (enExample) |
| EA (1) | EA201990875A1 (enExample) |
| IL (1) | IL265625A (enExample) |
| MX (1) | MX2019004775A (enExample) |
| MY (1) | MY200695A (enExample) |
| PE (1) | PE20191131A1 (enExample) |
| SG (1) | SG11201902857SA (enExample) |
| TW (2) | TWI784983B (enExample) |
| WO (1) | WO2018085555A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL291329B1 (en) | 2013-09-25 | 2025-09-01 | Cytomx Therapeutics Inc | Polypeptides that can be determined in matrix metalloproteinases and uses thereof |
| CN106459153B (zh) | 2014-01-31 | 2021-12-21 | 西托姆克斯治疗公司 | 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法 |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| KR102584340B1 (ko) | 2016-11-03 | 2023-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | 활성화가능한 항-ctla-4 항체 및 그의 용도 |
| CA3039316A1 (en) | 2016-11-28 | 2018-05-31 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| CN110177875B (zh) | 2016-11-28 | 2023-11-28 | 中外制药株式会社 | 包含抗原结合结构域和运送部分的多肽 |
| MX2019013648A (es) | 2017-05-19 | 2021-01-08 | Wuxi Biologics Shanghai Co Ltd | Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4). |
| CN111670051B (zh) | 2017-11-08 | 2024-06-25 | 亚飞（上海）生物医药科技有限公司 | 生物分子偶联物及其用途 |
| WO2019107384A1 (ja) | 2017-11-28 | 2019-06-06 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| BR112020010450A2 (pt) * | 2017-11-28 | 2020-11-24 | Chugai Seiyaku Kabushiki Kaisha | polipeptídeo que inclui domínio de ligação a antígeno e seção transportadora |
| EP3769309A1 (en) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
| MX2020012252A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina 12 activables y metodos de uso de los mismos. |
| US12077577B2 (en) | 2018-05-30 | 2024-09-03 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising aggrecan binding domain and carrying moiety |
| BR112021012631A2 (pt) | 2018-12-26 | 2021-12-14 | Xilio Dev Inc | Anticorpos anti-ctla4 e métodos de uso dos mesmos |
| AU2020234785A1 (en) | 2019-03-13 | 2021-08-19 | Merck Sharp & Dohme Llc | Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents |
| EP3955960B1 (en) | 2019-04-18 | 2025-01-15 | Bristol-Myers Squibb Company | Ipilimumab variants with enhanced specificity for binding at low ph |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| CN110498856B (zh) * | 2019-09-17 | 2020-08-11 | 浙江玉安康瑞生物科技有限公司 | 一种ctla-4单克隆抗体5h7及其用于抗肿瘤的用途 |
| US20220411499A1 (en) | 2019-11-08 | 2022-12-29 | Bristol-Myers Squibb Company | LAG-3 Antagonist Therapy for Melanoma |
| BR112022009631A2 (pt) | 2019-12-19 | 2022-08-09 | Bristol Myers Squibb Co | Combinações de inibidores de dgk e antagonistas do ponto de checagem |
| AU2021208642B2 (en) * | 2020-01-17 | 2025-06-05 | Immunelogic Therapeutics, Inc. | Pro-antibody that reduces off-target toxicity |
| IL296913A (en) * | 2020-04-01 | 2022-12-01 | Xilio Dev Inc | Il-12 masked cytokines and their cleavage products |
| KR20220166814A (ko) * | 2020-04-09 | 2022-12-19 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 항체를 함유하는 조성물 |
| AR122043A1 (es) | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| CN115803343A (zh) * | 2020-05-26 | 2023-03-14 | 百奥泰生物制药股份有限公司 | 多特异性抗体及其应用 |
| ES3040950T3 (en) | 2020-08-11 | 2025-11-06 | Janux Therapeutics Inc | Cleavable linker compositions and methods |
| MX2023006817A (es) | 2020-12-09 | 2023-08-14 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras. |
| CN116917325A (zh) * | 2021-03-01 | 2023-10-20 | 西里欧发展公司 | 用于治疗癌症的被掩蔽的ctla4和pd1/pdl1抗体的组合 |
| CN117500834A (zh) | 2021-06-21 | 2024-02-02 | 百时美施贵宝公司 | 使用蔗糖、甘露糖醇和甘氨酸来减少高浓度冻干生物制剂药物产品的重构时间 |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| WO2023183888A1 (en) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| EP4499685A1 (en) | 2022-03-25 | 2025-02-05 | CytomX Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
| EP4504257A1 (en) | 2022-04-01 | 2025-02-12 | CytomX Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| JP2025511187A (ja) | 2022-04-01 | 2025-04-15 | サイトムエックス セラピューティクス，インク． | Ｃｄ３結合タンパク質及びその使用方法 |
| WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
| AR130076A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| WO2024030858A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| EP4565690A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| AR130079A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| WO2024030850A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| WO2024031032A1 (en) | 2022-08-05 | 2024-02-08 | Bristol-Myers Squibb Company | Anti-ctla-4 antibodies for treatment of kras mutant cancers |
| EP4582453A1 (en) * | 2022-09-02 | 2025-07-09 | Cichlid Inc. | Anti-ctla-4 monoclonal antibody and use thereof |
| CN120936384A (zh) | 2023-04-12 | 2025-11-11 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2024216194A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2025114529A1 (en) | 2023-12-01 | 2025-06-05 | Ablynx Nv | Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| US20250361320A1 (en) | 2024-02-27 | 2025-11-27 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| EP4658320A1 (en) | 2024-02-27 | 2025-12-10 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| EP1286700A2 (en) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| AU9399501A (en) | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| CN1930288B (zh) | 2002-04-09 | 2012-08-08 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| WO2006089231A2 (en) | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| AU2006284651C1 (en) | 2005-08-31 | 2013-09-12 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| ES2396569T3 (es) | 2006-01-17 | 2013-02-22 | Medarex, Inc. | Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo y xilosilo |
| CA2645347A1 (en) | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| CA2663536A1 (en) | 2006-10-24 | 2008-05-02 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| US8263073B2 (en) | 2008-02-04 | 2012-09-11 | Medarex, Inc. | Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CN102076865B (zh) | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物 |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2010081173A2 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| IL279304B (en) * | 2011-02-15 | 2022-07-01 | Immunogen Inc | Method for producing an indolinobenzodiazepine |
| PL2699264T3 (pl) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1 |
| EP2710042A2 (en) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| US8852599B2 (en) * | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| AU2013251310B2 (en) * | 2012-04-27 | 2018-02-15 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| CN104736168B (zh) | 2012-05-31 | 2018-09-21 | 索伦托治疗有限公司 | 与pd-l1结合的抗原结合蛋白 |
| CA2876904C (en) | 2012-06-22 | 2019-12-03 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| DK2925350T3 (da) * | 2012-12-03 | 2019-05-13 | Bristol Myers Squibb Co | Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| EP3003370B1 (en) | 2013-05-28 | 2020-01-22 | Dcb-Usa Llc | Antibody locker for the inactivation of protein drug |
| CN111423511B (zh) | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | 与pd-1结合的抗原结合蛋白 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| BR112016007547A2 (pt) * | 2013-10-07 | 2018-01-23 | Prestige Biopharma Pte. Ltd. | ?vetor de expressão bicistrônico para expressão de anticorpos e método para a produção de anticorpos usando o mesmo? |
| PE20160953A1 (es) | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2016004383A1 (en) | 2014-07-03 | 2016-01-07 | City Of Hope | Tumor-selective ctla-4 antagonists |
| WO2016014974A2 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| CA2971734C (en) | 2014-12-22 | 2025-11-18 | Enumeral Biomedical Holdings Inc | Anti-pd-1 antibodies |
| EP3244907B1 (en) * | 2015-01-13 | 2020-02-19 | City of Hope | Ctla4-binding protein peptide-linker masks |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| MX2017011644A (es) * | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| EP3307777A4 (en) | 2015-06-11 | 2019-02-13 | Wuxi Biologics (Shanghai) Co. Ltd. | NOVEL ANTI-PD-L1 ANTIBODIES |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| FI3334763T3 (fi) | 2015-08-11 | 2024-10-30 | Wuxi Biologics Ireland Ltd | Uusia pd-l1-vasta-aineita |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| HK1257840A1 (zh) | 2015-09-01 | 2019-11-01 | Agenus Inc. | 抗-pd-1抗体及其使用方法 |
| TW202208440A (zh) | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
| EP3402512A4 (en) | 2016-01-11 | 2019-09-25 | Armo Biosciences, Inc. | INTERLEUKIN-10 IN THE PREPARATION OF ANTIGEN-SPECIFIC CD8 + T CELLS AND METHOD FOR THE USE THEREOF |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| KR102584340B1 (ko) | 2016-11-03 | 2023-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | 활성화가능한 항-ctla-4 항체 및 그의 용도 |
| WO2018213335A1 (en) | 2017-05-16 | 2018-11-22 | Scalmibio, Inc. | Activatable antibodies and methods of use thereof |
| US11623965B2 (en) | 2017-08-16 | 2023-04-11 | Bristol-Myers Squibb Company | Prodruggable antibodies, prodrugs thereof, and methods of use and making |
-
2017
- 2017-11-02 KR KR1020197015448A patent/KR102584340B1/ko active Active
- 2017-11-02 EP EP17837917.8A patent/EP3535300B1/en active Active
- 2017-11-02 EA EA201990875A patent/EA201990875A1/ru unknown
- 2017-11-02 SG SG11201902857SA patent/SG11201902857SA/en unknown
- 2017-11-02 US US16/347,522 patent/US11117968B2/en active Active
- 2017-11-02 JP JP2019523779A patent/JP7039582B2/ja active Active
- 2017-11-02 BR BR112019008223A patent/BR112019008223A2/pt unknown
- 2017-11-02 PE PE2019000902A patent/PE20191131A1/es unknown
- 2017-11-02 CA CA3042679A patent/CA3042679A1/en active Pending
- 2017-11-02 WO PCT/US2017/059740 patent/WO2018085555A1/en not_active Ceased
- 2017-11-02 MX MX2019004775A patent/MX2019004775A/es unknown
- 2017-11-02 MY MYPI2019002439A patent/MY200695A/en unknown
- 2017-11-02 AU AU2017355446A patent/AU2017355446A1/en not_active Abandoned
- 2017-11-02 KR KR1020237032965A patent/KR102814027B1/ko active Active
- 2017-11-02 CN CN201780066620.7A patent/CN110072890B/zh active Active
- 2017-11-03 TW TW106138139A patent/TWI784983B/zh not_active IP Right Cessation
- 2017-11-03 TW TW111141621A patent/TW202334213A/zh unknown
- 2017-11-03 AR ARP170103060A patent/AR110678A1/es unknown
-
2019
- 2019-03-26 IL IL265625A patent/IL265625A/en unknown
- 2019-04-30 CO CONC2019/0004469A patent/CO2019004469A2/es unknown
- 2019-05-03 CL CL2019001226A patent/CL2019001226A1/es unknown
-
2021
- 2021-08-11 US US17/399,729 patent/US12441799B2/en active Active
-
2022
- 2022-03-09 JP JP2022036450A patent/JP7472183B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3535300A1 (en) | 2019-09-11 |
| US20190359714A1 (en) | 2019-11-28 |
| JP2020500016A (ja) | 2020-01-09 |
| CO2019004469A2 (es) | 2019-05-10 |
| TW202334213A (zh) | 2023-09-01 |
| CN110072890A (zh) | 2019-07-30 |
| KR102584340B1 (ko) | 2023-10-10 |
| WO2018085555A1 (en) | 2018-05-11 |
| KR20190072626A (ko) | 2019-06-25 |
| CN110072890B (zh) | 2022-11-29 |
| CA3042679A1 (en) | 2018-05-11 |
| JP2022091800A (ja) | 2022-06-21 |
| TW201819412A (zh) | 2018-06-01 |
| KR20230141941A (ko) | 2023-10-10 |
| US12441799B2 (en) | 2025-10-14 |
| PE20191131A1 (es) | 2019-09-02 |
| KR102814027B1 (ko) | 2025-05-27 |
| US11117968B2 (en) | 2021-09-14 |
| AR110678A1 (es) | 2019-04-24 |
| US20220089734A1 (en) | 2022-03-24 |
| JP7039582B2 (ja) | 2022-03-22 |
| SG11201902857SA (en) | 2019-05-30 |
| TWI784983B (zh) | 2022-12-01 |
| IL265625A (en) | 2019-05-30 |
| AU2017355446A1 (en) | 2019-05-02 |
| JP7472183B2 (ja) | 2024-04-22 |
| EA201990875A1 (ru) | 2019-09-30 |
| WO2018085555A8 (en) | 2018-05-31 |
| MY200695A (en) | 2024-01-11 |
| MX2019004775A (es) | 2019-08-05 |
| EP3535300B1 (en) | 2025-10-22 |
| BR112019008223A2 (pt) | 2019-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001226A1 (es) | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) activables y sus usos. | |
| CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
| CL2020000216A1 (es) | Anticuerpos anti-ctla-4 y sus usos. | |
| CO2019012353A2 (es) | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1 | |
| CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
| MX2019006598A (es) | Celulas asesinas naturales modificadas geneticamente y sus usos. | |
| MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CO2022000260A2 (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus métodos de uso | |
| UY37194A (es) | Inmunomoduladores | |
| PE20201419A1 (es) | Anticuerpos anti-hla-g y utilizacion de los mismos | |
| AR120147A1 (es) | Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco | |
| CL2024000459A1 (es) | Tubulisinas y conjugados de proteína-tubulisina. | |
| CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| CL2020002624A1 (es) | Formulaciones de inmunoconjugado anti-cd79b estables. | |
| MX2018010993A (es) | Derivados de icariina e icaritina. | |
| MX2021003838A (es) | Derivados de proteina hmgb1 para la eliminacion de biopeliculas. | |
| MX2023009146A (es) | Anticuerpos y usos de estos. | |
| DOP2021000113A (es) | Anticuerpos antiperiostina y usos de estos | |
| MX2020012788A (es) | Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso. | |
| CO2023012326A2 (es) | Receptores de antígeno sintético de cadena única y de cadena múltiple para células inmunológicas diversas | |
| CL2022001138A1 (es) | Anticuerpos tmem219 y usos terapéuticos de los mismos | |
| MX2021011334A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| MX2021015228A (es) | Metodos y composiciones para mejorar resultados de pacientes con cancer. | |
| MX2020012964A (es) | Metodos para el tratamiento de cancer de vejiga. | |
| AR119973A1 (es) | Composiciones y métodos de anticuerpos anti-cd39 |